Needham, HC Wainwright, and Wedbush maintain buy ratings for G1 Therapeutics with respective price targets of $12, $9, and $5.

Needham & Company LLC reaffirmed its buy rating for G1 Therapeutics (NASDAQ:GTHX) with a $12.00 price objective, joining HC Wainwright's buy rating and $9.00 price target, and Wedbush's outperform rating and $5.00 price target. G1 Therapeutics has a market cap of $213.83m, a P/E ratio of -6.60 and a beta of 1.71. Its shares opened at $4.09 on 1 May, with a 50-day moving average of $4.30 and a 200-day moving average of $3.41.